Top Industry Leaders in the Leuprolide Acetate Market
Cipla Launches Leuprolide Acetate Injection Depot (22.5mg):In November 2022, Cipla announced the launch of its Leuprolide Acetate Injection Depot 22.5mg in the US. This is a generic version of AbbVie's Lupron Depot® and is expected to increase competition in the market.
Amneal Biosciences Receives FDA approval for Leuprolide Acetate Injection:In July 2023, Amneal Biosciences received FDA approval for its Leuprolide Acetate Injection for the palliative treatment of advanced prostate cancer.
Tolmar Affirms Full Supply of Eligard® (Leuprolide Acetate):In August 2020, Tolmar Pharmaceuticals confirmed the full availability of its Eligard® (leuprolide acetate) for injectable suspension in all doses. This was in response to reports of a shortage of a different leuprolide acetate injection product in the US.
List of Leuprolide Acetate Key Companies in the Market
- Varian Pharmed (Iran)
- avenit AG (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Sun Pharmaceutical Industries Ltd. (India)
- Livzon Pharmaceutical Group Co.Ltd. (China)
- Beijing Biote Pharmaceutical Co.Ltd (China)
- Soho-YImIng (China)
- AbbVie Inc. (U.S.)
- Sanofi (France)
- Astellas Pharma (Japan)
- Abbott (U.S)
- Merck KGaA (Germany)
- Pfizer Inc. (U.S.)